Evidence map›Paper›PMID 32117698›Full record

ReviewEuroasian journal of hepato-gastroenterology

Update on Immunosuppression in Liver Transplantation.

Burcak E Tasdogan, Michelle Ma, Cem Simsek, Behnam Saberi, Ahmet Gurakar

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Euroasian journal of hepato-gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
–field-weighted citation impact, top 71% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Ototoxicity of Immunosuppressant Drugs: A Systematic Review.The journal of international advanced otology · 2022
    Pooled it
  2. Pooled it
  3. Comparative analysis of early post-transplant infections after DCD with hypothermic oxygenated liver perfusion and DBD liver transplantation: A retrospective cohort study.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2026
    Article
  4. Article
  5. Side Effects of Immunosuppressant Drugs After Liver Transplant.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. The Effect of Genetic HLA Matching on Liver Transplantation Outcome: A Systematic Review and Meta-Analysis.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2023
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Liver transplantation during global COVID-19 pandemic.World journal of clinical cases · 2021
    Review
  18. Review
  19. Movement Disorders and Liver Disease.Movement disorders clinical practice · 2021
    Review
  20. Immunosuppressive Drugs in Liver Transplant: An Insight.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Burcak E TasdoganDepartment of Gastroenterology and Hepatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Michelle MaDepartment of Gastroenterology and Hepatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Cem SimsekDepartment of Gastroenterology and Hepatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Behnam SaberiDepartment of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, USA.
Ahmet GurakarDepartment of Gastroenterology and Hepatology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins Medicine · USIcahn School of Medicine at Mount Sinai · USJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The standard therapy for decompensated end-stage chronic liver disease of any etiology and acute fulminant hepatic failure is liver transplantation (LT). Advances in immunosuppressive therapy decreased the rates of acute and chronic rejections. Thus, graft and patient survivals have significantly improved. However, long-term adverse effects of prolonged use of immunosuppressive agents such as malignancies, opportunistic infections, metabolic disorders, and other organ toxicities have now become a major concern. Consequently, alternative approaches are needed to deescalate the customary drugs and their side effects. Therapy must be individualized and additional preventive measures should be taken by patients with particular risk factors or predisposed to certain adverse effects. Current opinion favors a combination of agents with different mechanism of actions and toxicity profiles. Corticosteroids are employed in immediate and early postoperative period. Although they have a pronounced side effect profile, calcineurin inhibitors (CNIs) are still the backbone of early and late phase immunosuppressive regimens because of their proved efficacy. Antimetabolites are frequent choices for steroid and/or CNI-sparing strategies. Studies also have established a role for mammalian target of rapamycin (mTOR) inhibitors in specific groups of recipients. Biologic agents are a hot topic of interest and made their way into current strategies for induction. Agents extrapolated from other transplantation or immunologic experience are being evaluated. HOW TO CITE THIS ARTICLE: Tasdogan BE, Ma M, Simsek C,

Indexed as

Adverse effectsImmunosuppressionLiver transplantation

Identifiers

PMID32117698
PMCPMC7047305
OpenAlexW2999579626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.